ALK Abello stock up 5% after strong first-quarter earnings

Published 06/05/2025, 09:10
ALK Abello stock up 5% after strong first-quarter earnings

Investing.com -- Shares of ALK Abello climbed 5% following the company’s release of its first-quarter results, which surpassed expectations with a 2% revenue increase driven by robust international tablet sales and other products.

The company’s focus on European tablets met forecasts, despite a slight miss excluding inventory stocking effects. The improved gross margin and significantly reduced operating costs led to a substantial earnings before interest and taxes (EBIT) beat, with a 30.8% EBIT margin, partially attributed to seasonal factors.

In the first quarter, ALK Abello’s sales outperformed consensus estimates, with tablet sales 3% above expectations, primarily due to strong performance in Japan. Other products also exceeded projections by 9%, countering the 2% shortfall in subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) drops. Notably, the intake of new tablet patients for the 2024/25 season increased by more than 10% compared to the previous year.

The company’s EBIT reached DKK 469 million, comfortably outpacing the consensus estimate of DKK 392 million. The EBIT margin of 30.8% also surpassed the consensus of 26.2%.

ALK Abello also reiterated its 2025 outlook, maintaining its revenue growth target of 9%-13% at constant exchange rates, with expectations at the higher end of the range. The EBIT margin forecast remains at approximately 25%, in line with current estimates. The company anticipates double-digit growth in tablet sales across all regions, mainly driven by volume growth, with a slight increase in gross margin expected.

The initial launches of the neffy product in the European Union are slated for the third quarter of 2025. The company’s commentary regarding minimal exposure to tariffs amid global trade uncertainties is likely to reassure investors, suggesting no significant impact on ALK’s growth or earnings for 2025.

The positive results and outlook for ALK Abello reflect the company’s strategic initiatives, including the recent co-promotion deal with ARS, which is seen as a prudent approach to expanding the U.S. salesforce footprint. While the deal is expected to yield synergies, they may take time to materialize. The company’s phase II peanut allergy tablet study is also progressing as planned, further underpinning the positive sentiment in the stock.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.